Real-Life Data on Mirabegron in Neurogenic Bladder Dysfunction
Conclusions: Mirabegron is continued in more than half of patients with neurogenic lower urinary tract dysfunction for more than 6 months. Further research is needed to identify eventual predictive factors.Urol Int
Source: Urologia Internationalis - Category: Urology & Nephrology Source Type: research
More News: Beta-Blockers | Brain | Dementia | Multiple Sclerosis | Neurology | Parkinson's Disease | Study | Urology & Nephrology